Artesunate 120mg powder for injection (Guilin Pharmaceutical Co., Ltd), MA90 LABELLING. Page 1 of 6

Similar documents
Artesunate 60 mg for injection WHOPAR part 5 June 2013 (Guilin Pharmaceutical Co., Ltd.), MA051 LABELLING

Sulfamethoxazole/Trimethoprim 400mg/80mg Tablets (Micro Labs Ltd), HA598. WHOPAR part 5 July 2017 LABELLING

Artesunate/amodiaquine 100/270 mg WHOPAR part 5 03/2009, version 1.0 (Sanofi-Aventis) MA058 LABELING

Lamivudine Tablets 150 mg (Macleods Pharmaceuticals Ltd), HA424. WHOPAR Part 5 05/2011, version 1.0 LABELLING. Page 1 of 8

Artesunate 60 mg for injection WHOPAR part 3 November 2015 (Guilin Pharmaceutical Co., Ltd.), MA051 PATIENT INFORMATION LEAFLET

Artesunate 60 mg for injection WHOPAR part 3 June 2013 (Guilin Pharmaceutical Co., Ltd.), MA051 PATIENT INFORMATION LEAFLET

WHOPAR part 5 Suppliers submission of the SRA approved text

Artemether 20mg/lumefantrine 120mg WHOPAR part 5 12/2011 Dispersible tablets (Novartis Pharma AG), MA069 LABELLING. Page 1 of 6

JSC «Olainfarm», Latvia PAS-Na 5.52 g Powder for oral solutions

PATIENT INFORMATION LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the patient. NEGABAN 1g, powder for solution for injection or infusion Temocillin

RECONSTITUTION, DOSING AND ADMINISTRATION

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX III LABELLING AND PACKAGE LEAFLET

PART 1.B SPC, LABELLING AND PACKAGE LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/17

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the user. Novastan 100 mg/ml concentrate for solution for infusion. argatroban monohydrate

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

PATIENT / USER INFORMATION LEAFLET. Cinryze 500 Units powder and solvent for solution for injection C1 inhibitor (human)

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

WHOPAR Part 3 March Zinc (as sulfate monohydrate) 20 mg Tablets (Macleods Pharmaceuticals Ltd), DI005 PACKAGE LEAFLET.

PACKAGE LEAFLET: INFORMATION FOR THE USER. Dopamine 40 mg/ml Sterile Concentrate

Package leaflet: Information for the user

PATIENT INFORMATION LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Paul-Ehrlich-Institut DE/V/0022/001/II/023/G Page 1

Package leaflet: Information for the patient. Hexvix 85 mg, powder and solvent for intravesical solution Hexaminolevulinate

Package leaflet: Information for the user Zinforo 600 mg powder for concentrate for solution for infusion Ceftaroline fosamil

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/16

PART 1 B SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET

Package leaflet: Information for the user. /.../ 50 mg powder and solvent for solution for injection/infusion. melphalan

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the user. Lidocaine Hydrochloride 1% w/v Solution for Injection Lidocaine Hydrochloride

Package leaflet: Information for the user. Portrazza 800 mg concentrate for solution for infusion necitumumab

PATIENT INFORMATION LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PACKAGE LEAFLET: INFORMATION FOR THE USER. Actilyse Cathflo 2 mg, poeder voor oplossing voor injectie en infusie. Alteplase

Package leaflet: Information for the patient. Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion daunorubicin and cytarabine

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the user. Carmellose sodium

Ventolin Injection 500 micrograms/ml salbutamol sulfate

Package leaflet: Information for the user. Pharmalgen Bee Venom Pharmalgen Wasp Venom. 100μg/ml. powder and solvent for solution for injection

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. (em-plis-city)

Package leaflet: Information for the user. Exembol 1 mg/ml solution for infusion. argatroban monohydrate

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

PACKAGE LEAFLET: INFORMATION FOR THE USER. Active substance: enoximone

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. SPC-0095-rev02_

PACKAGE LEAFLET: INFORMATION FOR THE USER. Variquel 1 mg powder and solvent for solution for injection Terlipressin acetate

2. What you need to know before you are given Konakion MM. Package Leaflet: Information for the patient

NITHIODOTE Solution for Injection. Active Substances Sodium Nitrite and Sodium Thiosulfate

Artecef 50/Artecef 150 (ARTECEF BV) WHOPAR part 4 09/2008, version 1.0 MA027/028 SUMMARY OF PRODUCT CHARACTERISTICS. Page 1 of 7

COMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH)

Package leaflet: Information for the user

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the user

Package leaflet: Information for the user. Tobramycin 40 mg/ml Solution for Injection tobramycin

Package leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid

COMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH)

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

PACKAGE LEAFLET: INFORMATION FOR THE USER. Calcium Folinate 10 mg/ml Injection

Package leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PACKAGE LEAFLET: INFORMATION FOR THE USER

B. PACKAGE LEAFLET 1

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

[Version 8, 10/2012] ANNEX I SUMMARY OF PROPOSED PRODUCT CHARACTERISTICS

Package leaflet: Information for the patient. Trasylol 10,000 KIU/ml solution for injection or infusion. Aprotinin

Transcription:

LABELLING Page 1 of 6

PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer Carton 1. NAME OF THE MEDICINAL PRODUCT Artesun 120mg * 2. STATEMENT OF ACTIVE SUBSTANCE Each vial contains 120 mg artesunate powder for injection. 3. LIST OF EXCIPIENTS Artesunate powder for injection does not contain any excipients. Solvent (sodium bicarbonate injection) contains sodium bicarbonate and water for injection. Diluent (sodium chloride injection) contains sodium chloride and water for injection. 4. PHARMACEUTICAL FORM AND CONTENTS Each box contains 1 vial of Artesunate for injection (120 mg) and 1 ampoule of 2 ml Sodium bicarbonate injection (50mg/ml) and 1 ampoule of 10 ml Sodium chloride injection (9mg/ml). 5. METHOD AND ROUTE OF ADMINISTRATION Intramuscular or intravenous use after reconstitution and dilution. Read the patient information leaflet before use. 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN Keep out of the sight and reach of children. 7. OTHER SPECIAL WARNING(S), IF NECESSARY 8. EXPIRY DATE * Trade names are not prequalified by WHO. This is the national medicines regulatory authority s (NMRA) responsibility. Throughout this WHOPAR the proprietary name is given as an example only. Page 2 of 6

EXP {MM/YYYY} 9. SPECIAL STORAGE CONDITIONS Store below 30 C. Protect from light. The reconstituted solution should be stored below 30 o C and should be used within one hour. 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 11. NAME AND ADDRESS OF THE SUPPLIER Guilin Pharmaceutical Co., Ltd.; No. 43 Qilidian Road Guilin, Guangxi China, 541004 12. WHO REFERENCE NUMBER (PREQUALIFICATION PROGRAMME) MA090 13. MANUFACTURER S BATCH NUMBER Batch {number} 14. (ADVICE ON) GENERAL CLASSIFICATION FOR SUPPLY Medicinal product subject to medical prescription. 15. INSTRUCTIONS ON USE Page 3 of 6

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Powder vial 1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Artesun 120mg Artesunate for injection 2. METHOD OF ADMINISTRATION I.M./I.V. USE 3. EXPIRY DATE EXP {DD/MM/YYYY} 4. MANUFACTURER S BATCH NUMBER Batch {number} 5. CONTENTS BY WEIGHT, BY VOLUME, OR BY UNIT 120 mg 6. OTHER Sterile Page 4 of 6

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Solvent ampoule 1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Sodium Bicarbonate Injection 2. LIST OF EXCIPIENTS Sodium bicarbonate (50 mg/ampoule) Water for injections (2 ml/ampoule) 3. PHARMACEUTICAL FORM AND CONTENTS Sodium Bicarbonate Injection 2 ml 100 mg (50 mg/ml) 4. EXPIRY DATE EXP {DD/MM/YYYY} 5. MANUFACTURER S BATCH NUMBER Batch {number} 5. CONTENTS BY WEIGHT, BY VOLUME, OR BY UNIT 2 ml 6. OTHER Sterile Page 5 of 6

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Diluent ampoule 1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Sodium Chloride Injection 2. LIST OF EXCIPIENTS Sodium Chloride (90 mg/ampoule) Water for injections (10 ml/ampoule) 3. PHARMACEUTICAL FORM AND CONTENTS Sodium Chloride Injection 10 ml 90 mg (9 mg/ml) 4. EXPIRY DATE EXP {DD/MM/YYYY} 5. MANUFACTURER S BATCH NUMBER 5. CONTENTS BY WEIGHT, BY VOLUME, OR BY UNIT 10 ml 6. OTHER Sterile Page 6 of 6